Description

CJC-1295 is a synthetic analog of growth hormone–releasing hormone (GHRH) engineered to extend half-life and enhance receptor binding stability in laboratory settings. In controlled research environments, it is studied for its interaction with GHRH receptors and downstream growth hormone signaling pathways.

Due to structural modifications designed to improve pharmacokinetic persistence in experimental models, CJC-1295 is commonly utilized in endocrine signaling research and pulsatile growth hormone release investigations. Researchers examine its influence on the hypothalamic–pituitary axis and its role in modulating insulin-like growth factor (IGF-1) pathway activity under laboratory conditions.

In preclinical frameworks, CJC-1295 is frequently explored for:

GHRH receptor activation studies

Growth hormone secretion modeling

Endocrine axis pathway research

IGF-1 signaling investigations

Long-acting peptide pharmacokinetic analysis

Its extended activity profile makes it relevant for sustained receptor engagement studies in controlled experimental systems.

Strictly intended for laboratory research use only. Not for human or veterinary use.